Insilico, HLFM Partner on AI Longevity Models
Insilico Medicine and Human Life Foundation Models, Inc. (HLFM) have entered into a multi-million-dollar collaboration to develop what the companies describe as the biotechnology industry’s first large-scale artificial intelligence foundation models dedicated to human longevity science, marking a significant push into AI-powered preventive medicine and aging research.
The partnership combines Insilico Medicine’s expertise in generative AI-driven drug discovery with HLFM’s access to large-scale biological and clinical datasets to create advanced AI systems capable of decoding the biological mechanisms of aging, predicting disease risk, and supporting the development of interventions designed to extend healthy lifespan.
The collaboration comes as longevity science gains momentum as a major economic and healthcare focus. Aging populations worldwide are reshaping labor markets, healthcare systems, and consumer demand, increasing pressure to develop strategies that can extend healthy years of life while reducing chronic disease burdens. According to market analysis cited by the companies, the global longevity sector is currently valued at approximately $5.3 trillion and is projected to reach $8 trillion by 2030.
Artificial intelligence has increasingly emerged as a key tool in aging research, enabling scientists to model biological aging pathways, identify disease biomarkers, predict health risks, and accelerate drug discovery. Insilico and HLFM aim to build on these advances by creating a “super-intelligence” AI foundation model tailored specifically for longevity science and predictive healthcare.
Under the agreement, Insilico will contribute expertise in multimodal foundation model development, deep learning systems engineering, and AI training frameworks. The company plans to use its MMAI Gym platform to establish model architectures, training systems, benchmarking standards, and computational algorithms to support the project.
HLFM, a newly launched company established by Human Longevity, Inc., will integrate these technologies with Human Longevity’s extensive de-identified biological and clinical datasets. Human Longevity has spent more than a decade compiling one of the world’s largest integrated collections of multi-omic data, imaging records, and longitudinal health information from thousands of individuals.
The companies believe combining advanced algorithms with large-scale biological datasets could enable foundation models capable of detecting, diagnosing, and managing disease with clinical-grade precision. They expect future applications to include early identification of age-related illnesses, predictive risk modeling for chronic diseases, and discovery of new AI-driven therapeutics and personalized interventions aimed at extending healthy lifespan.
Executives involved in the collaboration described the effort as a step toward transforming medicine from a reactive system focused on disease treatment to a preventive model centered on longevity and health maintenance.
Alex Zhavoronkov, founder, chief executive officer, and chief business officer of Insilico Medicine, said the collaboration seeks to build a next-generation AI system capable of decoding aging biology by combining Insilico’s expertise in generative AI and multimodal models with HLFM’s biological datasets. He said the initiative could help identify disease risks earlier, uncover new therapeutic targets, and improve precision in longevity-focused drug discovery.
Wei-Wu He, executive chairman of Human Longevity, said the partnership advances the company’s founding vision of combining biological data and artificial intelligence to fundamentally change medicine. He added that the initiative aims to develop systems capable of predicting complex diseases years or even decades before symptoms emerge while informing interventions that promote healthy aging.
Longevity science has remained central to Insilico’s strategy since its inception. The company first gained industry attention in 2015 when Zhavoronkov highlighted the potential role of advanced computing in aging research at NVIDIA’s technology conference, asking whether computing power could eventually help cure aging. More recently, Insilico established a longevity advisory board chaired by Andrew Adams of Eli Lilly and Company to accelerate AI-driven aging research.
If successful, the collaboration could help establish a new frontier in healthcare, where AI not only assists in treating disease but also anticipates and prevents it through data-driven longevity science.